These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1298 related items for PubMed ID: 28658478

  • 1. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.
    Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R.
    JAMA Cardiol; 2017 Aug 01; 2(8):855-862. PubMed ID: 28658478
    [Abstract] [Full Text] [Related]

  • 2. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2014 Jan 01; 7(1):55-63. PubMed ID: 24332419
    [Abstract] [Full Text] [Related]

  • 3. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
    Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Stanco G, Rosato G, Suryapranata H, De Luca G.
    JACC Cardiovasc Interv; 2014 Aug 01; 7(8):849-56. PubMed ID: 25147029
    [Abstract] [Full Text] [Related]

  • 4. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents.
    Giustino G, Baber U, Stefanini GG, Aquino M, Stone GW, Sartori S, Steg PG, Wijns W, Smits PC, Jeger RV, Leon MB, Windecker S, Serruys PW, Morice MC, Camenzind E, Weisz G, Kandzari D, Dangas GD, Mastoris I, Von Birgelen C, Galatius S, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R.
    Am J Cardiol; 2015 Sep 15; 116(6):845-52. PubMed ID: 26174605
    [Abstract] [Full Text] [Related]

  • 5. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
    Colleran R, Kufner S, Harada Y, Giacoppo D, Cassese S, Repp J, Wiebe J, Lohaus R, Lahmann A, Schneider S, Ibrahim T, Laugwitz KL, Kastrati A, Byrne RA, Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Investigators.
    Catheter Cardiovasc Interv; 2017 Feb 15; 89(3):367-374. PubMed ID: 27377301
    [Abstract] [Full Text] [Related]

  • 6. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2013 Aug 15; 6(8):777-89. PubMed ID: 23968698
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction.
    Chichareon P, Modolo R, Collet C, Tenekecioglu E, Vink MA, Oh PC, Ahn JM, Musto C, Díaz de la Llera LS, Cho YS, Violini R, Park SJ, Suryapranata H, Piek JJ, de Winter RJ, Wykrzykowska JJ, Spaulding C, Kang WC, Slagboom T, Hofma SH, Wijnbergen IF, Di Lorenzo E, Pijls NH, Räber L, Brugaletta S, Sabaté M, Stoll HP, Stone GW, Windecker S, Onuma Y, Serruys PW.
    J Am Coll Cardiol; 2019 Nov 26; 74(21):2572-2584. PubMed ID: 31753202
    [Abstract] [Full Text] [Related]

  • 8. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
    De Luca G, Sauro R, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Palmieri V, Serino V, Rosato G, Suryapranata H, Di Lorenzo E.
    Diab Vasc Dis Res; 2015 Sep 26; 12(5):306-14. PubMed ID: 26150193
    [Abstract] [Full Text] [Related]

  • 9. Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial.
    van Houwelingen KG, Lam MK, Löwik MM, Danse PW, Tjon Joe Gin RM, Jessurun GA, Anthonio RL, Sen H, Linssen GCM, IJzerman MJ, Doggen CJM, von Birgelen C.
    Rev Esp Cardiol (Engl Ed); 2016 Dec 26; 69(12):1152-1159. PubMed ID: 27595181
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.
    Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW.
    J Am Coll Cardiol; 2013 Aug 06; 62(6):496-504. PubMed ID: 23747778
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
    Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D'Ascenzo F, Frati G, Mancone M, Genereux P, Stone GW.
    J Am Coll Cardiol; 2014 Feb 04; 63(4):299-307. PubMed ID: 24211507
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M, Dörig M, Frangieh AH, Ghadri JR, Cammann VL, Diekmann J, Napp LC, D'Ascenzo F, Imori Y, Obeid S, Maier W, Lüscher TF, Templin C.
    Catheter Cardiovasc Interv; 2016 Nov 15; 88(6):E173-E182. PubMed ID: 27377554
    [Abstract] [Full Text] [Related]

  • 13. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, Valgimigli M, Tölg R, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A.
    Clin Res Cardiol; 2016 Jul 15; 105(7):575-84. PubMed ID: 26689707
    [Abstract] [Full Text] [Related]

  • 14. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis.
    Giustino G, Baber U, Aquino M, Sartori S, Stone GW, Leon MB, Genereux P, Dangas GD, Chandrasekhar J, Kimura T, Salianski O, Stefanini GG, Steg PG, Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Saporito R, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R.
    JACC Cardiovasc Interv; 2016 Apr 11; 9(7):674-84. PubMed ID: 27056305
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program.
    Widimsky P, Motovska Z, Belardi J, Serruys P, Silber S, Windecker S, Neumann FJ.
    Int J Cardiol; 2013 Oct 09; 168(4):3522-6. PubMed ID: 23706326
    [Abstract] [Full Text] [Related]

  • 16. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
    Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Hernádez-Antolín R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vázquez N, Backx B, Serruys PW.
    JACC Cardiovasc Interv; 2014 Jan 09; 7(1):64-71. PubMed ID: 24332423
    [Abstract] [Full Text] [Related]

  • 17. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ.
    JACC Cardiovasc Interv; 2011 Jan 09; 4(1):24-9. PubMed ID: 21251625
    [Abstract] [Full Text] [Related]

  • 18. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF, Muller O, Heg D, Roffi M, Kurz DJ, Moarof I, Weilenmann D, Kaiser C, Tapponnier M, Stortecky S, Losdat S, Eeckhout E, Valgimigli M, Odutayo A, Zwahlen M, Jüni P, Windecker S, Pilgrim T.
    Lancet; 2019 Oct 05; 394(10205):1243-1253. PubMed ID: 31488372
    [Abstract] [Full Text] [Related]

  • 19. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
    Zocca P, Kok MM, Tandjung K, Danse PW, Jessurun GAJ, Hautvast RWM, van Houwelingen KG, Stoel MG, Schramm AR, Tjon Joe Gin RM, de Man FHAF, Hartmann M, Louwerenburg JHW, Linssen GCM, Löwik MM, Doggen CJM, von Birgelen C.
    JACC Cardiovasc Interv; 2018 Mar 12; 11(5):462-469. PubMed ID: 29519378
    [Abstract] [Full Text] [Related]

  • 20. Long-term results of the randomized comparison of everolimus-eluting stents and sirolimus-eluting stent in patients with ST elevation myocardial infarction (RACES-MI trial).
    Di Lorenzo E, Sauro R, Capasso M, Lanni F, Lanzillo T, Carbone G, Manganelli F, Palmieri V, Serino V, Pagliuca MR, Rosato G, Suryapranata H, De Luca G.
    Int J Cardiol; 2016 Jan 01; 202():177-82. PubMed ID: 26397405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.